The invention concerns B-domain truncated Factor VIII molecules with a modified circulatory half-life, wherein the molecules are covalently conjugated with a hydrophillic polymer via an O-linked oligosaccharide in the truncated B domain, and wherein factor VIII activation results in removal of the covalently conjugated hydrophillic polymer, as well as pharmaceutical compositions comprising said Factor VIII molecules.